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Crohn disease (CD) exhibits a 2–4-fold increased frequency in Jews as compared with other ethnic/racial groups.
Three coding variants of the NOD2/CARD15 have been reported as independent disease-predisposing mutations
(DPMs), but these were found in only 30%–40% of patients with CD and could not account for all the linkage
between CD and the IBD1 locus. The aim of the present study was to explore whether additional DPMs at the
IBD1 locus exist in the high-risk Jewish group. Sixty-four Ashkenazi Jewish and 147 non-Jewish white families
were studied. Six microsatellite markers spanning IBD1 were genotyped for linkage analysis in subgroups stratified
on NOD2/CARD15 DPM status. SNPs in NOD2/CARD15 (R702W, G908R, 1007fs, and S268P) were then geno-
typed in family and independent case-control samples. On the basis of initial results, sequencing was done on
NOD2/CARD15-translated regions in 12 Jewish individuals. Subsequently, a new NOD2/CARD15 variant was
genotyped and analyzed. After excluding the influence of the three DPMs, significant linkage of IBD1 to CD in
Jews remained with two peaks at D16S403 (mean allele sharing [MAS] p 0.70] and D16S411 (MAS p 0.59).
Further, we observed an increased frequency of a haplotype carrying only the 268S variant in Jewish patients (OR
p 3.13, ) but not in non-Jews, suggesting the existence of a Jewish-specific additional disease-predisposingPp .0023
factor on this haplotype. Sequencing of this haplotype revealed a new variant (IVS8+158; JW1). The 268S-JW1
combination exhibited a further increased risk (OR p 5.75, ) and the highest population-attributablePp .0005
risk (15.1%) for CD among reported DPMs in Jews. In Ashkenazi Jews, unrecognized population-specific predis-
posing factor(s) exist on the 268S-JW1 haplotype at the IBD1 locus. This factor may contribute to the higher risk
for CD in Ashkenazi Jews as compared with non-Jews.
Introduction
Crohn disease (CD [MIM 266600]) is one of the two
major forms of chronic inflammatory bowel disease (IBD)
and can affect any part of the gastrointestinal tract. The
cumulative risk of surgical treatment for patients with
CD reaches 60% in 10 years after onset because of the
fistulizing, perforating, stricturing, and/or obstructing
complications of CD, thereby severely affecting patients’
quality of life.
Although the pathogenesis of CD has not been fully
elucidated, CD appears to be a multifactorial/oligogenic
disease, with both environmental and genetic factors con-
tributing to its etiology. The role of genetic factors in the
etiology of CD has been supported by studies of ethnic
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differences, familial aggregation, and twin and spouse
data (Yang and Rotter 2000). With regard to ethnic
variation, a consistently increased incidence (2.0–4.0
times) and prevalence rate (2.2–9.4 times) of CD in the
Jewish population have been documented, compared
with other ethnic groups in the same geographic area
(Rotter et al. 1992). These observations are considered
to be evidence for a strong genetic predisposition to the
etiology of CD and have led to the hypothesis that the
higher risk of CD in the Jewish population is due, at
least in part, to genetic factors.
Hugot et al. (1996) mapped the IBD1 gene to the
proximal region of the long arm of chromosome 16
(16q12) in the white population, utilizing genomewide
scan linkage strategies. This finding has been replicated
in many studies, including an international collaborative
study reporting a remarkably high multipoint linkage
score (MLS) for a complex disease ( atMLSp 5.7
marker D16S411 in 16q12) (Ohmen et al. 1996; Parkes
et al. 1996; Cho et al. 1997; Brant et al. 1998; Cavan-
augh et al. 1998; Curran et al. 1998; Annese et al. 1999;
Hampe et al. 1999; Akolkar et al. 2001; the IBD In-
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ternational Genetics Consortium 2001). The IBD1
locus has also been demonstrated to be significantly
linked with CD in Jewish families (Cho et al. 1997;
Akolkar et al. 2001). Recently, the IBD1 gene (NOD2/
CARD15) was simultaneously identified by a positional-
cloning strategy (Hugot et al. 2001) and a positional
candidate gene strategy (Hampe et al. 2001; Ogura et
al. 2001a). The NOD2/CARD15 molecule is expressed
primarily in monocytes and activates NF-kB through
interaction with its N-terminal caspase recruitment do-
mains (CARDs) (Ogura et al. 2001b). Three coding poly-
morphisms or variants (R702W, G908R, and 1007fs,
denoted elsewhere as SNP8, 12, and 13, respectively;
Hugot et al. 2001) in NOD2/CARD15 were shown to
be independently associated with CD (Hugot et al.
2001), with the most significant evidence for 1007fs,
which results in a frameshift in the 10th leucine-rich
repeat and is followed by a premature stop codon. This
truncation mutation in the NOD2/CARD15 molecule
appears to result in an inability to activate NF-kB in
response to bacterial lipopolysaccharides (Ogura et al.
2001a). All three of these disease-predisposing muta-
tions (DPMs) are found on the same background hap-
lotype, which can be identified by several other SNPs,
including P268S (denoted elsewhere as SNP5; Hugot et
al. 2001). However, an average of 60%–70% of pa-
tients with CD do not have any of the three NOD2/
CARD15 DPMs (Abreu et al. 2002; Ahmad et al. 2002;
Cuthbert et al. 2002; Hampe et al. 2002b; Lesage et al.
2002; Vermeire et al. 2002). These three predisposing
mutations do not account for all of the linkage between
CD and the IBD1 locus, since residual evidence of
linkage in the region is observed after families with
the variants are removed (Hugot et al. 2001; Hampe
2002a).
Because of the unique evolutionary history of the Ash-
kenazi Jewish population (Motulsky 1979, 1995), one
might expect that the genes predisposing to CD in the
Jewish population would be more homogeneous than
those in the general white population (Diamond and
Rotter 2002). A study of the Ashkenazi Jewish popu-
lation with high incidence of CD should yield increased
power and more specific haplotype information to iden-
tify genetic variants that are associated with CD, in a
manner analogous to the specific BRCA1 and BRCA2
mutations occurring in the Jewish population (Struew-
ing et al. 1997; Moslehi et al. 2000). Thus, to determine
if additional DPMs exist at the IBD1 locus in the high-
risk Jewish group, we first tested if there was remaining
evidence for linkage after excluding the influence of the
three known causative mutations (702W, 908R, and
1007fs). We then examined the association between CD
and the known causative mutations and a background
variant. Significant association of CD with a background
haplotype in the Jewish population then led us to se-
quence the translated region ofNOD2/CARD15 to iden-
tify additional DPMs in this gene. These studies resulted
in identification of a new haplotype for NOD2/
CARD15 that is a major factor predisposing to CD in
Ashkenazi Jews.
Subjects and Methods
Study Subjects
A total of 211 families with CD (64 Ashkenazi-Jewish
and 147 non-Jewish white families) were studied, con-
sisting of 373 patients with CD and 672 unaffected rel-
atives. The probands of all families were ascertained
from the IBD Center at Cedars-Sinai Medical Center or
referred to us by gastroenterologists or the Crohn’s Co-
litis Foundation of America nationwide. These families
have at least one family member affected with CD and
do not have any known individuals affected with ulcer-
ative colitis. In these 211 families, 91 multiplex families
with CD that included sib pairs with CD were available
for linkage analysis (28 Ashkenazi-Jewish and 63 non-
Jewish families). In addition, an independent case-con-
trol panel (112 Ashkenazi-Jewish and 166 non-Jewish
patients with CD and 79 Ashkenazi-Jewish and 143 non-
Jewish control individuals) was also included in this study.
Controls were recruited from spouses, married-in rela-
tives, or acquaintances who had no known IBD or other
autoimmune diseases or family history of IBD. The pre-
sent study, as a part of an ongoing IBD genetic study, was
reviewed and approved by the Human Subject Institu-
tional Review Board at Cedars-Sinai Medical Center.
Genotyping and Sequencing Analysis
To conduct the linkage study, we genotyped six micro-
satellite markers spanning the IBD1 locus, covering 34
cM on chromosome 16 (D16S403, D16S753, D16S409,
D16S411, D16S419, and D16S408) using an ABI 377
automated DNA analyzer and associated software (Ap-
plied Biosystems). For association analysis of NOD2/
CARD15, we genotyped all families with CD and case-
control samples for SNPs, including the three principal
DPMs (R702W, G908R, and 1007fs), one background
SNP (P268S), and a new SNP (IVS8158 [CrT], JW1),
identified by us after sequencing (see below), by the Taq-
man MGB bialleic discrimination system using an ABI
7900 instrument (Applied Biosystems).
All the sequenced individuals ( ) were of Ash-Np 12
kenazi Jewish origin.DNA sequences ofNOD2/CARD15
exons, including the 5′ UTR and splicing signal regions,
were analyzed, according to the protocol of the Big Dye
Terminator Ready Reaction kits (Applied Biosystems).
Sequencing primers were the same as PCR primers except
for exon 9, in which nested primers were used (table 1).
Sequence data were analyzed on an ABI 377 DNA ana-
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Table 1
Primers Used for PCR and Sequencing NOD2/CARD15
Exon Forward Primer Reverse Primer
Size
(bp)
Annealing Temperature
(C)
Ex1 TCTCCTCCCCAGATGTTTAAGATG CCAGCCAAGGATGCCACAGC 856 63
Ex2 TGCCTTCTCTGGGTCTCAAT ATGGACCAAGTTACCCCACA 751 53
Ex3 GACTGCCCTTCCCTTTCTG ACATTGCTCCATCAGCCTTC 200 55
Ex4D CAGAGCCCCTTCCCGTCATC AGCACAGTGTCCGCATCGTCATTG 625 65
Ex4C CTGGAGGAGCTCTTCAGCAC AACAGTTCCTGGTGGCATTT 668 60
Ex4B CCTGCTCCAAGAGACCTCAG TCAGATGTCTGGCACTCAGC 678 60
Ex4A AGATCACAGCAGCCTTCCTG ATCTGGGCAGTGTTGCAAAG 582 60
Ex5&6 TTTTGGGGGATTTGTAGATT CTGGGGAGATCACAGCATTAGAGA 631 54
Ex7 ACTCTCTCCCTGGCTTGTC CGTCCCGCTGCCCCTTTC 435 55
Ex8 GAGGCCACTCTGGGATTGAG CCTGATCCAGCCCAATATCTT 463 57
Ex9 TGCCAGGCACTATATTAAGGT GGGCTGGATCAGGTACATT 878 53
Ex10 CTTTATTGGTTACCTTCACTTC GCTGCAATGGAGAGTGGG 654 55
Ex11 GATGGCACGGGTACTCTT ACTGAGGTTCGGAGAGCTAAA 511 56
Ex12 GAGGGCACCAGGGTTTGCTCA GATCAGCAGAGGCCAGTCCCATAC 698 56
Ex9 nested primer CCCCAGAGCAGAGAATCC CTTTCCCTGCTCTGACATAC 55
NOTE.—Exon 4 was divided into five overlapping areas and individually sequenced.
lyzer with associated software, and alignments were per-
formed using BioEdit.
Statistical Analysis
Two-point nonparametric linkage analyses were per-
formed separately by use of SIBPAL from the Statistical
Analysis for Genetic Epidemiology (SAGE) version 3.1
package on the Jewish and non-Jewish multiplex fami-
lies. Family-based association was evaluated by a trans-
mission/disequilibrium test (TDT) (Spielman et al. 1993)
in all families with CD. Since only 29% of the families
were multiplex families, and there was no difference in
the TDT results between simplex and multiplex families,
we report the results from all families combined. To per-
form the TDT, GENEHUNTER2 (Kruglyak et al. 1996)
was used for four-locus SNP haplotypes, and SIMWALK2
(Sobel and Lange 1996) was used to construct haplo-
types for five SNPs. In the case-control samples, PHASE
was used to construct haplotypes (Stephens et al. 2001).
Haplotypic genotype frequencies were compared between
case and control individuals, using the x2 test. Odds ratio
(OR) and its 95% CI were calculated for each risk hap-
lotype, referenced to the same low-risk haplotype by the
Mantel-Haenszel method (Schlesselman 1982). Popu-
lation-attributable risk (PAR) was estimated under the
assumption that the frequency of a risk haplotype in the
control group can be regarded as approximately rep-
resentative of the target population and the OR as an
approximation of the relative risk. Thus, PARp
, where Pe p frequencyPe(OR 1)/[Pe(OR  1) 1]
of a risk haplotype in the control group (Schlesselman
1982).
Results
Stratified Linkage Analysis on the NOD2/CARD15
Genotype
When the families were analyzed in each ethnic group,
we found a trend toward increased mean allele sharing
(MAS) at markers D16S403 (31 Mb from NOD2/
CARD15, MAS 0.55, ) and D16S411 (1.8 MbPp .11
from NOD2/CARD15,MAS 0.54, ) in the Jew-Pp .20
ish families with CD. In the non-Jewish families with CD,
increased MASs (10.50) were observed at all marker
positions, with the peak at marker D16S411 (MAS 0.56,
), but they did not attain statistical significancePp .094
in this sample size.
When we divided the Jewish families into NOD2/
CARD15 DPMs and CARD15 DPMs subgroups on
the basis of the possession of any of the three principal
DPMs in the family, the evidence for linkage in families
DPM for NOD2/CARD15 increased and reached a
significant level, with the two peaks at marker D16S403
( , ) at proximal 16p and atMASp 0.70 Pp .0008
marker D16S411 ( , ) at proximalMASp 0.59 Pp .1
16q near NOD2/CARD15 (fig. 1). In contrast, in the
non-Jewish families with CD, the significantly increased
MAS was observed only in families DPM for NOD2/
CARD15 (the highest at D16S411,MASp 0.61 Pp
), whereas there was no evidence for any MAS.0075
increase in families DPM for NOD2/CARD15
( ) (fig. 1). These results indicated aMASp 0.47–0.52
different contribution of the three known DPMs to the
IBD1 linkage of CD between the two ethnic groups and
raised the possibility that additional predisposing gene(s)
or additional NOD2/CARD15 DPM(s) exist at the
IBD1 locus and play a more important role in the sus-
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Table 2
TDT of the NOD2/CARD15 Haplotypes in
Ashkenazi-Jewish and Non-Jewish White
Families with CD
Haplotypea
TDT IN
ASHKENAZI
JEWS
TDT IN
NON-JEWISH
WHITES
T/NT P Value T/NT P Value
702W 2/4 42/11 .000021
908R 13/2 .0045 10/6
1007fs 5/4 34/12 .0012
268S alone 8/5 31/38
No variant 16/27 36/85
a The haplotypes 702W, 908R, and 1007fs repre-
sent the haplotype that has the rare variant of each
mutation. All 702W, 908R, and 1007fs haplotypes
also possess the rare variant of the background SNP
(268S).
Figure 1 MAS in multiplex families with Crohn disease before and after stratification on presence or absence of three principal NOD2/
CARD15 DPMs (702W, 908R, and 1007fs). Six microsatellite markers spanning NOD2/CARD15 locus on chromosome 16 were genotyped
(from left to right, D16S403, D16S753, D16S409, D16S411, D16S419, and D16S408, respectively). Left panel, Jewish families. Right panel,
non-Jewish families. Black circles represent the MAS from entire families (prestratification) in each ethnic group. White triangles represent the
MASs in the families where there are no principal NOD2/CARD15 DPMs, and white squares represent the MASs in families with principal
NOD2/CARD15 DPMs, after stratification.
ceptibility to CD in the Jewish population when com-
pared with the non-Jewish population.
TDT
We performed the family-based association test (using
the TDT method) to investigate any ethnic differences
of the CD association with the three known NOD2/
CARD15 DPMs. We observed that all the 702W, 908R,
or 1007fs variants almost always (98%) occur on a com-
mon background haplotype, which contains the 268S
variant, and that the 702W, 908R, and 1007fs variants
were never found on the same haplotype in both family
groups.
In the non-Jewish families, there were very significant
associations with 702W (transmitted/not transmitted [T/
NT]: 42/11, ) and 1007fs (T/NT: 34/12,Pp .000021
), and there was also an increased frequencyPp .0012
of transmission with 908R (T/NT: 10/6), but this was
not statistically significant (table 2). Although the num-
ber of families was moderate, we did observe a signifi-
cant association between CD and the 908R haplotype
(T/NT: 13/2, ) in the Jewish families. Mean-Pp .0045
while, the association of the 1007fs and of the 702W
variants to CD was not observed. Furthermore, there
appeared to be a preferential transmission of the hap-
lotype with only the background variant (268S) in Jew-
ish (T/NT: 8/5) but not in non-Jewish families (T/NT:
31/38), though this excess in Jews did not attain statis-
tical significance. Although the lack of association with
certain DPMs in Jewish families and preferential trans-
mission of 268S alone could be due to the small sample
size, the apparent ethnic difference in allele transmission
led us to test these DPMs further in a larger ethnically
matched case-control sample.
Case-Control Study
We examined haplotypic genotypes in an independent
Jewish and non-Jewish case-control panel. Because of
small numbers in rare allele homozygotes and compound
heterozygotes, we combined the rare allele homozygotes
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Table 3
Association Results of NOD2/CARD15 Haplotype Groups Defined by Four SNPs in Ashkenazi-Jewish
and Non-Jewish White Patients with CD
FOUR-SNP-LOCUS-
HAPLOTYPEa
ASSOCIATION IN ASHKENAZI JEWS ASSOCIATION IN NON-JEWISH WHITES
CD
(%)
Control
(%) P Value OR 95% CI
CD
(%)
Control
(%) P Value OR 95% CI
702W (2211) 7.1 6.3 .25 2.00 0.6–6.6 13.8 6.9 .022 2.50 1.1–5.6
908R (2121) 12.5 8.8 .067 2.50 0.9–6.8 5.4 3.5 .24 1.96 .6–6.1
1007fs (2112) 10.7 2.5 .0041 7.50 1.6–35.5 7.8 2.8 .025 3.54 1.1–11.3
268S alone (2111) 31.2 17.7 .0023 3.13 1.5–6.6 22.2 26.5 .83 1.06 .6–1.8
Other 2.6 1.2 .23 3.75 0.4–37.4 3.0 0 .022
Reference 35.7 63.2 47.5 60.1
a Each haplotype group consists of individuals with the following haplotypic genotype. The four-SNP positions are
P268S, R702W, G908R, and 1007fs, respectively. 1 p wild type; 2 p the rare variant of the SNP.; 702W (2211) p
heterozygote or homozygote of 702W; 908R (2121) p heterozygote or homozygote of 908R; 1007fs (2112)p hetero-
zygote or homozygote of 1007fs; 268S alone (2111)p heterozygote or homozygote of 268S without any of other three
DPMs; Other p compound heterozygotes; Reference p homozygotes of wild type on all SNPs.
with heterozygotes and also lumped all other rare haplo-
types together so that six main haplotypic groups were
formed (table 3).
In comparable sample sizes, we observed a significant
association between the haplotype with the frameshift
mutation (1007fs) and CD in both the Jewish (ORp
, ) and non-Jewish samples (7.50 Pp .0041 ORp
, ) (combined ). Increases of the3.54 Pp .024 P ! .001
908R haplotype were seen in both ethnic groups, al-
though the association did not attain statistical signifi-
cance in the non-Jewish group, probably because of low
frequency of this haplotype in the non-Jewish popula-
tion. With regard to the 702W haplotype, we observed
a significant association with CD ( ,ORp 2.50 Pp
) in the non-Jewish population only. In the Jewish.022
population, the association of the 702W haplotype did
not reach statistical significance, although an increased
OR was observed , ).(ORp 2.00 Pp .24
It was intriguing that we observed a highly significant
association between the haplotype carrying only the
background variant (268S alone haplotype) and CD in
the Jewish sample ( , ) but no ev-ORp 3.13 Pp .0023
idence for association of this haplotype in non-Jews
( , ). These data indicated that theORp 1.06 Pp .834
268S alone haplotype predisposes to risk for CD in Jews
and might contain an as-yet-unrecognized predisposing
mutation(s).
Sequence Analysis
To search for possible unrecognized mutation(s) on
the 268S alone haplotype in Jews, we sequenced the
NOD2/CARD15 exons, including the 5′ UTR and splic-
ing-signal regions in 12 Jewish individuals. These con-
sisted of seven patients with CD with the 268S-alone
haplotype (CD1–CD7; fig. 2), three patients (CD8–
CD10), and two normal control individuals (NC1 and
NC2) without the 268S variant. We found 12 sequence
variants, 10 identified elsewhere and 2 newly identified
variants, namely intervening sequence (IVS) (a8 158
variant of this SNP is denoted as “JW1”) and R791Q.
The is a CrT mutation in the palindromeIVS8 158
sequence in the intron 8 splicing region, and R791Q is
a GrA nonsynonymous mutation in exon 4, causing an
amino acid substitution of arginine to glutamine. We did
not find any nonsynonymous mutation commonly pos-
sessed by Jewish patients with CD with the 268S-alone
haplotype. Figure 2 shows the position of these variants
in the 12 sequenced individuals. Nine of the 12 variants
were found in the Jewish patients with the 268S-alone
haplotype. The most common variant observed in those
patients was IVS10–133 (SNP9). In addition, 5′ UTR–59
(rs2076752), S178S (rs2067085), R459R (SNP6),
R587R (SNP7), R791Q, IVS8158 (JW1), V955I, and
IVS1064 (rs1077861) were also observed.
Genotyping of the IVS8158 (JW1)
Of the nine variants observed in the patients with the
268S-alone haplotype, the only common variant not doc-
umented elsewhere was the newly identified IVS8158
(JW1). We therefore genotyped this JW1 variant as a
possible DPM or as a marker identifying a disease-pre-
disposing haplotype. Since the available sample size in
the Jewish families was limited, we utilized the case-
control panel to investigate the role of the JW1 variant.
This JW1 variant also showed linkage disequilibrium
(LD)with other reportedDPMs. In the Jewishpopulation,
all the 1007fs or 702W variants occurred on the same
haplotype as JW1. In contrast, the 908R variant occurred
on the haplotype that did not possess JW1 (fig. 3). This
trend was similarly observed in the non-Jewish groups.
Meanwhile, the 268S-alone haplotype was divided into
two haplotype groups on the basis of the possession of
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Figure 2 NOD2/CARD15 polymorphisms observed in P268S-alone haplotypes in Ashkenazi Jewish patients with CD. CD1 and CD2
are homozygous patients with the P268S rare allele without known three DPMs (702W, 908R, and 1007fs). CD3–CD7 are heterozygous patients
with 268S without the three DPMs. CD8–CD10 are patients and NC1 and NC2 are normal control individuals without any of four variants
(268S and three DPMs). IVS p Intervening sequences; 1 p Common allele; 2 p Rare allele.
Figure 3 Haplotype structure of the five NOD2/CARD15 var-
iants genotyped in this study. The letters in white squares indicate the
variant (rare allele) of each SNP. The capital letters S, W, and R rep-
resent the amino acid variants serine, tryptophan, and arginine, re-
spectively. The small letter t represents the nucleotide variant thymine
at the JW1 SNP, and fs represents the frameshift mutation at the 1007fs
SNP.
the JW1 variant in both ethnic groups. The new JW1
variant is located telomeric to P268S SNP and is almost
always accompanied by the 268S variant (272/283p
) similar to the other three principal DPMs.96%
In this haplotypic-genotype analysis, we observed a
strong association of the 268S-JW1 haplotype (without
the three known DPMs) with CD in Jews, independent
of the other DPM haplotype groups (table 4). Compar-
ing within the 268S-alone haplotype group, the 268S-
JW1 haplotype showed a remarkably increased associ-
ation ( ), and the most significant P valueORp 5.75
( ) among all DPM haplotype groups in thePp .0005
Jewish population. Furthermore, the 268S-JW1 group
in the Ashkenazi Jews showed the highest population-
attributable risk (PAR, 15.1%) among all DPM groups
(fig. 4). When the 268S-JW1 haplotype was taken into
account, the population-attributable risk of NOD2/
CARD15 risk variants in Ashkenazi Jews became 28.3%,
which was double the PAR of the three DPMs observed
in non-Jewish whites (14.6%).
The 268S-JW1() haplotype did not show any disease
association in the Jewish population. In addition, in the
non-Jewish population, we did not find any association
with either the 268S-JW1() haplotype (CD 15.6% vs.
control 15.3%) or the 268S-JW1() haplotype (6.6%
vs. 11.1%).
A phylogenetic tree of NOD2/CARD15 haplotypes
comprising five genotyped SNPs (P268S, R702W,G908R,
1007fs, and IVS8158[JW1]) was constructed with the
use of CLUSTALW (Thompson et al. 1994; fig. 5). In this
tree, the 908R haplotype forms a separate branch,
whereas haplotypes of 268S-JW1, 1007fs, and 702W
compose a related group characterized by the possession
of the JW1 variant. However, in the JW1 group, the 702W
haplotype hardly contributed to the risk of CD in the
Jewish patients ( ); conversely, the 268S-PARp 0.8%
JW1 haplotype hardly contributed to the risk of CD in
the non-Jewish patients ( ). Therefore, wePARp 0.3%
did not delineate a common ancestral haplotype repre-
senting the susceptibility to CD in both ethnic groups.
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Figure 4 PAR of each CARD15-predisposing haplotype in Ash-
kenazi Jews and non-Jewish whites. The variant names in this figure
represent each risk haplotype defined in table 3 and table 4.
Table 4
Association Results of NOD2/CARD15 Haplotype Groups Defined by JW1 in Ashkenazi-Jewish and Non-Jewish
White Patients with CD
FIVE-SNP-LOCUS
HAPLOTYPE a
ASSOCIATION IN ASHKENAZI JEWS ASSOCIATION IN NON-JEWISH WHITES
CD
(%)
Control
(%) P Value OR 95% CI
CD
(%)
Control
(%) P Value OR 95% CI
268S-JW1 20.5 6.3 .0005 5.75 2.0–16.4 15.6 15.3 .4431 1.29 .7–2.5
268S-JW1() 10.7 11.3 .29 1.67 .6–4.3 6.6 11.1 .4908 .75 .3–1.7
NOTE.—The 268S-JW1 and 268S-JW1() groups are the two subgroups of the “268S Alone” group in table 3,
defined by presence or absence of the JW1 rare variant. The association was tested in comparison with the “Reference”
group, as defined in table 3.
a Each haplotype group under “five-SNP-locus haplotype” consists of individuals with the following haplotypicgenotype.
Each SNP position is P268S, R702W, G908R, JW1, and 1007fs, respectively. “1” means wild type; “2” is the rare
variant of the SNP. 268S-JW1 (without other three DPMs): 21121/11111, 21121/21111, 21121/21121, 21121/11121.
268S-JW1() (without other three DPMs): 11111/21111, 21111/21111.
This seems to suggest that an additional causative fac-
tor exists on the 268S-JW1 haplotype in the Jewish
population.
Discussion
We report the delineation of a novel haplotype (268S-
JW1) for the susceptibility to CD in the Ashkenazi Jew-
ish population at the IBD1 locus on chromosome 16.
Although we did not find a new common nonsynony-
mous variant of NOD2/CARD15 on this haplotype,
268S-JW1 appeared to contribute predominantly to the
risk of CD in Jews, as it presented the highest popula-
tion-attributable risk (15.1%) among NOD2/CARD15
variants in the Jewish population. This observation in-
dicates that JW1 is a variant that identifies an unrecog-
nized predisposing factor(s) to CD in the Jewish pop-
ulation. This factor(s) may account for some of the
increased susceptibility to CD in the Jewish population.
The JW1 variant reported here is located in the pal-
indrome sequence in intron 8; we could not identify any
new common coding mutation in NOD2/CARD15 on
this 268S-JW1 haplotype. Hence, there is a possibility
that this variant may affect the expression and function
of the NOD2/CARD15 molecule. But we found neither
signal sequences nor promoter sequence homology with
the JW1 sequence, and there was no preserved sequence
between human and mouse species around the JW1 var-
iation (WWWSignal Scan;WWWPromoter Scan; UCSC
Genome Bioinformatics). We also checked the splicing of
intron 8 in JW1 homozygous mononuclear cells, com-
paring with control cells without the JW1 mutation, yet
we did not find any change of splicing length in intron
8 (data not shown). Further, in the non-Jewish popu-
lation, we did not observe an association of the 268S-
JW1 haplotype with CD. Therefore, these available data
argue that the JW1 variant alone does not have a path-
ologic effect directly, but it more likely occurs in strong
LD with a population-specific causative factor in Jews.
Additional strategies will be required to identify the
Jewish-specific causative factor to elucidate the mech-
anisms of the high incidence and prevalence of CD in
the Jewish population.
In the Jewish families with CD who did not carry any
knownNOD2/CARD15DPMs, we observed the strong-
est evidence for linkage at marker D16S403 and an
increased mean allele sharing at marker D16S411, close
toNOD2/CARD15.This phenomenonwas not observed
in the non-Jewish population. These results indicate that
the relative extent of contribution of the three known
principal DPMs to the IBD1 linkage to CD is different
among ethnic groups, and imply the existence of ad-
ditional responsible haplotype(s) specific for CD in the
Jewish population.
The possible existence of population-specific respon-
sible factors and/or haplotypes other than known prin-
cipal DPMs in NOD2/CARD15 has been recently re-
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Figure 5 The phylogenetic tree of five haplotypes generated by
using CLUSTALW (a multiple alignments and tree-making program).
This tree indicates the relationships between the CD-associated haplo-
types in both Jewish and non-Jewish populations and a possible hap-
lotype development consisting of five genotyped SNPs (P268S,R702W,
G908R, 1007fs, and IVS8158 [JW1]).
ported by Hampe and his colleagues (2002a). After
excluding the influence of the known NOD2/CARD15
DPMs in German families with CD, they still observed
strong linkage for CD at marker D16S3068 in proximal
16p and at marker D16S3019 in central 16q and weak
linkage at marker D16S409 in proximal 16q. The
marker D16S3068 is located between D16S403 and
D16S753 in our study, and marker D16S409 is located
2.8 Mb centromeric to NOD2/CARD15. In addition,
Hampe et al. also observed an ethnic difference between
German and British families, as there was no remaining
linkage in British families with CD after the influence
of known DPMs was excluded. Our linkage results in
Jewish families were quite in accord with their obser-
vations and support the existence of additional popu-
lation-specific responsible factors and/or haplotypes on
chromosome 16.
The NOD2/CARD15 association with CD has been
observed in many populations (but not in all), such as
lack of association of the 908R variant in Norwegians
(haplotype frequency: CD 0.86%, control 1.2%)
(Hampe et al. 2002b) and the 908R variant in the Dutch
population (allele frequency: CD 4.3%, control 3.0%)
(Murillo et al. 2002). We did not observe a significant
association between 702W and CD in both family and
case-control studies in the Jewish population. These eth-
nic differences in the association of NOD2/CARD15
DPMs may be explained by the limited sample size or
by the low haplotype and allele frequencies in these pop-
ulations. Or this difference could imply that the positive
association and linkage of these DPMs (908R and/or
702W) to CD is based on LD between a common un-
known causative factor on their haplotypes and these
variants. However, as we did not identify a common
ancestral haplotype between Jewish and non-Jewish
populations (fig. 5), an additional causative factor seems
to exist on the 268S-JW1 haplotype in the Jewish
population.
In conclusion, we found a novel NOD2/CARD15
haplotype (268S-JW1) in Ashkenazi Jews to be strongly
associated with CD, and this haplotype appeared to
contribute to the higher incidence and prevalence of CD
in this population. Furthermore, we observed evidence
for the possible existence of a population-specific disease
causative factor(s) at the IBD1 locus and the possibility
of the ethnic-specific additional linkage on the short arm
of chromosome 16 in Ashkenazi Jewish patients with
CD. Further studies on this novel susceptible NOD2/
CARD15 haplotype (268S-JW1) should lead to the
identification of additional as-yet-unrecognized predis-
posing factor(s) to CD and contribute to our under-
standing of the underlying mechanism of the linkage of
IBD1 to CD.
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